Brain Glioma
Introduction
Gliomas are tumors that originate from glial cells in the brain, accounting for 40% to 60% of all primary central nervous system tumors and are known as the most common primary intracranial tumors in adults. Common types include diffuse astrocytomas, oligodendrogliomas, etc.
Why Choose China
Advanced Technologies
Chinese teams have developed a multimodal neuro-navigation technology based on functional imaging to address the challenge of highly infiltrative gliomas with indistinct boundaries. This series of studies is among the six highest-quality evidence-based medicine studies globally in this field (Neurosurg Rev 2015). Chinese teams pioneered the use of free radial artery bridging for intracranial-extracranial vascular bypass in treating refractory cerebrovascular diseases, a technique promoted by the World Federation of Neurosurgical Societies. Furthermore, they developed three new types of blood flow reconstruction tailored to high, medium, and low flow requirements, significantly improving the long-term efficacy rate of Moyamoya disease treatment to 93% and reducing the rebleeding rate from 7.1% to 1.9%.
Achievements
Chinese teams identified four new molecular subtypes of gliomas and described their characteristics, which are cited by the WHO as the only Asian contribution in their authoritative pathology guidelines on gliomas. Building on this, they established a molecular visualization navigation surgery system for gliomas, enabling rapid intraoperative detection of driver gene mutations, spatial heterogeneity mapping of molecular characteristics, and precise delineation of tumor infiltration boundaries. This transforms tumor resection from being based on surgeon experience to a “sculptural resection” guided by tumor molecular heterogeneity maps.
Experienced Doctors
To date, this approach has been applied in 3,100 cases, increasing the total resection rate of tumors in the motor function area from 51.7% to 72%, reducing the postoperative hemiplegia rate from 32.8% to 15.3%, and achieving a long-term aphasia rate of only 5.3% in language area tumor surgeries.
Brain Glioma
Introduction
Gliomas are tumors that originate from glial cells in the brain, accounting for 40% to 60% of all primary central nervous system tumors and are known as the most common primary intracranial tumors in adults. Common types include diffuse astrocytomas, oligodendrogliomas, etc.
Why Choose China
Advanced Technologies
Chinese teams have developed a multimodal neuro-navigation technology based on functional imaging to address the challenge of highly infiltrative gliomas with indistinct boundaries. This series of studies is among the six highest-quality evidence-based medicine studies globally in this field (Neurosurg Rev 2015). Chinese teams pioneered the use of free radial artery bridging for intracranial-extracranial vascular bypass in treating refractory cerebrovascular diseases, a technique promoted by the World Federation of Neurosurgical Societies. Furthermore, they developed three new types of blood flow reconstruction tailored to high, medium, and low flow requirements, significantly improving the long-term efficacy rate of Moyamoya disease treatment to 93% and reducing the rebleeding rate from 7.1% to 1.9%.
Achievements
Chinese teams identified four new molecular subtypes of gliomas and described their characteristics, which are cited by the WHO as the only Asian contribution in their authoritative pathology guidelines on gliomas. Building on this, they established a molecular visualization navigation surgery system for gliomas, enabling rapid intraoperative detection of driver gene mutations, spatial heterogeneity mapping of molecular characteristics, and precise delineation of tumor infiltration boundaries. This transforms tumor resection from being based on surgeon experience to a “sculptural resection” guided by tumor molecular heterogeneity maps.
Experienced Doctors
To date, this approach has been applied in 3,100 cases, increasing the total resection rate of tumors in the motor function area from 51.7% to 72%, reducing the postoperative hemiplegia rate from 32.8% to 15.3%, and achieving a long-term aphasia rate of only 5.3% in language area tumor surgeries.